VivoSim Labs, INC. (VIVS) stock
VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$0.12−0.00 (-2.91%)
Close on Nov 17, 2026Market cap $383.64KP/E –Yield –
VivoSim Labs r&d expenses
Research and development expenses are spending on new products and technology.
VivoSim Labs's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.32M, down 6.6% year over year. For fiscal 2026 it was $4.19M, down 16.6% from the year before. Over ten years it grew -13.6% a year on average. The highest annual figure on record is $19.55M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $4.19M | -16.6% |
| FY2025 | Mar 31, 2025 | $5.03M | -8.6% |
| FY2024 | Mar 31, 2024 | $5.50M | -38.1% |
| FY2023 | Mar 31, 2023 | $8.89M | +167.6% |
| FY2022 | Mar 31, 2022 | $3.32M | +201.0% |
| FY2021 | Mar 31, 2021 | $1.10M | -79.1% |
| FY2020 | Mar 31, 2020 | $5.28M | -64.2% |
| FY2019 | Mar 31, 2019 | $14.75M | -17.8% |
| FY2018 | Mar 31, 2018 | $17.96M | -8.1% |
| FY2017 | Mar 31, 2017 | $19.55M | +8.5% |
| FY2016 | Mar 31, 2016 | $18.01M | +39.4% |
| FY2015 | Mar 31, 2015 | $12.92M | +276.0% |
| FY2012 | Dec 31, 2012 | $3.44M | +142.0% |
| FY2011 | Dec 31, 2011 | $1.42M | +18.0% |
| FY2010 | Dec 31, 2010 | $1.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.13M | +13.1% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $1.13M | +31.0% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.14M | -36.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $923.00K | -6.2% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.00M | -28.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $859.00K | -19.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.78M | +24.1% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $984.00K | -26.3% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $1.40M | -15.8% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.06M | -80.5% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $1.43M | +21.0% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $1.34M | +8.4% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.67M | +63.3% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $5.45M | +380.1% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $1.19M | +28.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $1.23M | +81.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $1.02M | +75.9% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $1.14M | +68.6% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $926.00K | +130.3% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $679.00K | +2325.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $580.00K | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $673.00K | +364.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $402.00K | -72.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $28.00K | -99.3% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $0 | -100.0% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $145.00K | -96.2% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $1.45M | -54.7% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $3.82M | +13.1% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $4.40M | +10.8% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $3.78M | -5.6% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $3.19M | -35.5% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $3.38M | -32.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $3.97M | -28.2% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $4.01M | -20.3% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $4.94M | +8.8% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $5.03M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $5.53M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $5.02M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $4.54M | – |
See a number that looks wrong?